skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Are there fundamental or other reasons why this stock has lost about 20% of its value in the past 5 weeks? Does NAFTA II negatively impact it? I notice the CEO is also president and chairman. Does this pose a risk at this stage, or would do so if the firm got a lot bigger?
I enjoyed the seminar last week. Refreshing !
Read Answer Asked by TOM on October 29, 2018
Q: ABBV share price has slumped from approx. $95 to $82.50 in the past 5 days. Marinol was recently approved by the FDA. ABBV currently has a Forward P/E ratio of 10.72. I understand that the industry's average Forward P/E is 15.85.

What is your view of this stock. Seems like it might be an opportune time to buy and play the marijuana angle from a safe distance.

The Webinar yesterday was great. I hope there are more. Thank you for your services.
Read Answer Asked by Grant on October 26, 2018
Q: Hello. Can you point me in the direction of a few solid health sector, dividend paying stock options that would be suitable to hold within an RRSP? I’m looking at a five to eight year horizon and consider myself as a ‘low to moderate’ risk investor.
PS found recent ‘ How to Pick a Stock in 2018’ very helpful. Thanks!
Read Answer Asked by Heather on October 25, 2018
Q: In your reply to my previous question you mentioned you thought Reliq Management had misrepresented revenue. My understanding was that the items to be restated comprise part or all of the Accounts Receivable as reported end of March. Is it considered misrepresentation when A/R turn out to not be collectible do to an unexpected non-reimbursement? It doesn't seem as bad or the same as when Nortel was misrepresenting, booking sales in Texas that had not actually occurred. Any detail you can provide on how analysts view these kind of snafus is appreciated.
Read Answer Asked by John on October 19, 2018
Q: I still like Celgene, but I'm considering harvesting a tax loss on it. What pharma stocks would you recommend I replace it with? Or would you wait the 30 days and hope to buy CELG back at a similar level again? I think every ounce of bad news is baked into it and so it might have some big upside if things like the patent fight on Revlimid work out in CELG's favor.
Read Answer Asked by Alex on October 19, 2018
Q: Just as a follow up to my previous question and a comment I am sure is on many members mind. I see that RHT is up a bit today after the call. Maybe a dead cat bounce who knows. The dilemma in selling at a 75% loss is that I do not get the tax loss as its in my TFSA. I imagine many members are in the same predicament. What little is left in the security, will make such a small difference in the overall portfolio, I would rather hang on and hope that your first impression of the Company was correct. Not sure my mentality is appropriate here, but I would rather take the lesson and hold, than to sell and then see it go back up.

Thoughts?

KC
Read Answer Asked by Kelly on October 18, 2018
Q: With all the talk of an admittedly bad mistake (at best) by management, what has happened to the technology? Didn't you believe in iUgo and the accompanying smart phone app and the jump this company supposedly had in producing a superior remote monitoring product for chronic care patients? But they bruise their heals because they didn't understand CMS billing well enough and, oh well, so much for that technology? Is it great technology or not? Will it save government health care money or not? If it will, then surely CMS will come around and recognize this and eventually reimburse for the service, no? This all just seems odd that one day you're touting this company as having the one of the best technology stories in the health technology space, and the next they are a dog because they made a mistake. Is there no room for growing pains for a start up?
Read Answer Asked by John on October 18, 2018
Q: I know you have reservations about the company's history and certain individuals, but momentum has been good recently. On Oct. 17 at midday, about 120,000 shares ($1 million) traded in a few minutes, which I assume was an institutional order. Total volume for the day was near 600,000 shares, which has only occurred a few other times earlier this year, when the share price was much lower. Are you aware of any increasing institutional interest in VMD?
Read Answer Asked by David on October 17, 2018
Q: Hi Team, sold my shares of RHT this morning. Transferring remaining capital from sale to US RRSP for another healthcare name. Someone on T.V last night was screaming Medtronic for a buy ,from my own readings and research I see Stryker as a good choice. Between the 2 which has a better growth profile. Which would you choose. I own ABBV and BDX for a total healthcare exposure of 17%. I Thank-you in advance! Like usual,......Great work team! Sam
Read Answer Asked by sam on October 17, 2018
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!